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or lenalidomid regimen and cross-sectionally 45.07%/24.73%/8.51% were treated 
by lenalidomid/bortezomib/conventional chemotherapy regimens, mean time to 
progression was 0.81 year. In the 5th line-34.19%/18.36%/18.36% of patients were 
treated by lenalidomid/bortezomib/conventional chemotherapy regimens, mean-
time to progression was 0.88 years. In the 6th line-60.20% of patients were treated 
by conventional chemotherapy. ConClusions: This cross-sectional survey deter-
mined the prevalence and treatment strategies of MM patients in Slovakia accord-
ing to the treatment lines.
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objeCtives: To estimate health care resource use (HCRU) associated with the 
advanced melanoma management in Portugal and to calculate the resulting direct 
medical and non-medical costs. Methods: An expert panel with 6 clinicians from 
the main Portuguese centers treating patients with advanced melanoma was cre-
ated and assessed to estimate HCRU associated with the disease management. A 
two-stage modified Delphi technique was adopted. During the 1st round experts 
answered to a questionnaire concerning resource consumption associated with 
different phases of disease management. At the 2nd round experts discussed and 
validated the mean results obtained from the questionnaires, during a consensus 
meeting. Phases of disease considered were: treatment initiation, progression 
free, post-progression and terminal care. HCRU during progression free phase 
was estimated for two different subsets of patients, according to their previous 
treatment experience: ipilimumab-naïve patients and ipilimumab previously 
treated patients. Medical appointments, laboratory tests, imaging examinations, 
hospitalizations, radiotherapy/radiosurgery and concomitant medications were 
the resources considered. HCRU resulting from adverse events management was 
not included. Costs for each phase were obtained by multiplying mean estimates 
of HCRU by unit costs according to official sources. Oncology drugs costs were 
not included during the treatment phase. Results: Elicited costs per disease 
management phase were the following: 893.4 € for treatment initiation, 1280.4€ /3 
weeks and 1487.5€ /3 weeks for treatment phase, respectively for ipilimumab-naïve 
and ipilimumab previously treated patients. For the BSC phase the cost estimated 
was 1668.7 € /month and the total terminal care cost was 5920.8€ . ConClusions: 
Inpatient costs assumed major role during all phases (except treatment initiation). 
Patient monitoring through medical appointments, laboratory tests and imaging 
examinations had a higher share of resource consumption during treatment phase 
than for patients on BSC. The results from our research are of utmost importance 
to support the cost-effectiveness evaluation of new advanced melanoma treat-
ment strategies.
CANCer – Patient-reported outcomes & Patient Preference studies
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objeCtives: Adherence to oncologic treatment is a key factor to improve the 
survival of oncologic patients. Several clinical trials reveal non-adherence in these 
patients is common, affecting the health results negatively. The objective is to 
review the published evidence about adherence to oncologic treatment. Methods: 
Systematic review of published articles in PubMed about adherence to oncological 
treatments (January 2005-December 2014) in the European Union. Article selection 
by two independent investigators was based on title and abstract. In addition to 
the incapability to meet other inclusion criteria, the little quality of the results 
was ground for exclusion of a single article. Articles were classified according 
to trial design, type of cancer and adherence measurement method. Results: 
27 publications were analyzed, in which adherence data was described for nine 
different types of cancer and breast cancer was the most studied (51.9% of the 
articles). United Kingdom was the country that carried out the most clinical tri-
als (40.7%). 92.6% of the articles evaluated the adherence of female cohorts and 
48.2% evaluated both men and women cohorts. The most employed methodologies 
to measure adherence were Self-Report, MPR (Medication Possession Ratio) and 
MEMSTM (Electronic Medication Event Monitoring System). 7.4% of the articles 
reported adherence results, 48.2% of adherent to treatment patients and 44.4% of 
both. Adherence ranges fluctuated between 25.9% and 100% while the ranges of 
adherent patients oscillated between 7.84% and 92%. Age was one of the factors 
that affected adherence to oncological treatments (patients under 60 and over 75 
were less adherent to oncological treatments). ConClusions: Disparity in cri-
teria and measurement methods contributes to the great heterogeneity of adher-
ence and adherent patients published data. The poor adherence levels retrieved 
confirm the need of implementing healthcare interventions to foster adherence, 
given its impact on both oncological treatments effectiveness and healthcare 
systems sustainability.
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objeCtives: Electronic data capture of patient-reported outcomes (ePRO) offers effi-
ciency, greater accuracy and improved compliance vs paper. However, mode equiva-
lence and device usability needs to be demonstrated, per ISPOR ePRO Research 
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objeCtives: The objective of the AMEL study was to describe healthcare resource 
utilization (HCRU) among advanced melanoma patients according to the treat-
ment they received in order to assess the mean cost per line of therapy according 
to the treatment received. Methods: The study was a retrospective observa-
tional study using medical records. 33 physicians participated in the research. 
Each physician documented all of their patients diagnosed with advanced cuta-
neous melanoma between January 1st 2012 and October 31st 2012. Resource use 
related to hospitalizations, outpatient visits, radiotherapy and imaging tests 
were collected throughout the patient pathway, from diagnosis to end of the data 
extraction or death, whichever occurred first. The costing was based on ENCC 
reference costs. Results: After exclusion of the patients whose treatment was 
part of a clinical trial, HCRU could be assessed for 220 patients who received 1st 
line treatment, 144 2nd line and 67 3rd line. Hospital consumption increased 
together with the line of therapy. The proportion of patients experiencing at least 
one hospitalization was 46.4%, 50.7% and 62.7% in 1st, 2nd and 3rd line and the 
mean length of stay was 14,39, 15.6 and 17.3 days respectively. In 1st line, the main 
cause of hospitalization was treatment administration (41.2% of patients) while 
it was palliative care in 2nd and 3rd line (52.1% and 54.8%). Hospitalization due to 
treatment toxicities occurred in 18.6% of first line patients, with a mean length of 
stay of 20.21 days and was less frequent in 2nd and 3rd line (6.8 and 9.5%). After 
valorization, the mean hospital cost per patient was 1,526€ in 1st line, 2,098€ in 
2nd and 2,250€ in 3rdline. ConClusions: Health care consumption, including 
hospitalization, increased together with evolution of the disease, with the most 
costly period being the “terminal state”.
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objeCtives: Subcutaneous versions of different oncology therapies are available 
since few years for which the patient-relevant and hospital benefits have not been 
assessed in real life. Methods: In order to analyze the impact of subcutaneous 
administrations for rituximab or trastuzumab in comparison to the respective intra-
venous mode a primary research in Italy was executed. The study’s primary objec-
tives were to analyze the resource and cost implications from different perspectives 
(patient, medical staff) in real world. The route of administration was discussed 
and aligned with the participating centers in order to capture all relevant therapy 
parts. After the successful execution of a pilot study 33 centers in 6 regions in 
Italy were recruited to participate. Results: Significant time savings are achieved 
with the subcutaneous mode through significantly lower patient preparation time 
including less time preparing the actual dosing for each individual patient. The total 
time difference is 3.3 hours with rituximab in hematology (NHL) which adds up to 
23.55 hours for a full course of treatment per patient (overall preparation time: 40.1 
hours intravenous [95%CI: +0.47] vs 16.6 hours subcutaneous [95%CI: +0.2]). In early 
breast cancer (trastuzumab) the time saving is 3.3 hours for the first cycle and the 
total time saving for patient preparation is 17.2 hours (overall preparation time: 
38.8 hours intravenous [95%CI: +9.42] vs 21.6 hours subcutaneous [95%CI: +9.9]). 
Furthermore in both settings the time of medical stuff was reduced and could hence 
be used elsewhere. Finally in case wastage was experienced with intravenous thera-
pies there were significant reductions in wastage through the subcutaneous admin-
istration (93% to 100%) with cost savings of 6’057 € with rituximab subcutaneous 
and 28’399 € with trastuzumab subcutaneous administration, respectively for the 
full treatment course. ConClusions: There are significant resource and cost sav-
ings due to subcutaneous administration with rituximab and trastuzumab in Italy.
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objeCtives: The latest official national data on epidemiology of multiply mye-
loma (MM) are available for year 2008. Estimated incidence for 2015 represents in 
both sexes 311 cases (age-standardized (ASR-W) incidence 3.1/100,000), mortality 
176 cases (ASR-W 1.6/100,000), prevalence 1,715 patients. The objective of this 
cross-sectional survey was to define prevalence and treatment strategies used in 
MM patients according to the treatment lines and provide a basis for the budget 
impact analysis (BIA). Methods: Data on treatment of 656 MM patients from 7 
MM-centers in 2013 from whole Slovakia were collected and analyzed. Continuous 
variables were calculated using standard descriptive statistics methods Results: 
86.9% of patients were cross-sectionally on active treatment. In the 1st clinical 
stage (according to Durie and Salmon classification) were 13.03% of patients, in 
the 2nd clinical stage-32.07%, in the 3rd clinical stage-54.09%. The treatment 
strategies were as followed: In the 1st line-36.34% of patients underwent BMT, 
outside them 80.53% were on bortezomib regimen, mean-time to progression rep-
resented 2.31 years. In the 2nd line-22.83% (out of 36.34%) of patients underwent 
re-transplant, outside them 68.50% were on lenalidomid regimen, mean-time to 
progression was 1.65 years. In the 3rd line-42.84%/21.71%/12.97% of patients were 
on bortezomib/lenalidomid/bendamustine regimens, mean-time to progression 
represented 1.29 year. 40.88% of all registered patients were in 2013 treated by 
the 4th line, 90.45% out of them had previously been treated by bortezomib and/
